Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 19/20 | 0.53 |
| ▸ | DRD4 | P21917 | 19/20 | 0.53 |
| ▸ | DRD3 | P35462 | 19/20 | 0.53 |
| ▸ | DRD1 | P21728 | 12/20 | 0.53 |
| ▸ | HTR2A | P28223 | 11/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908005 | 0.91 | DRD2 (0.53) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL4906839 | 0.85 | DRD2 (0.62) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL3608123 | 0.79 | DRD2 (0.77) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL4918371 | 0.79 | HTR2A (0.53) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL4915561 | 0.77 | DRD2 (0.63) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL4913177 | 0.77 | DRD2 (0.50) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL5505000 | 0.76 | DRD2 (0.64) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL4914339 | 0.76 | DRD2 (0.50) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL4917921 | 0.76 | DRD4 (0.60) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL4916997 | 0.76 | DRD2 (0.54) | DRD2DRD4DRD3DRD1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778685-B1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SANOL ARZNEI SCHWARZ GMBH (DE) | 2008-03-26 | — | — | EP | claimed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | claimed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | GRIN2A, GRIN2C, GRIN1 | DRD2 248/4885DRD4 166/4885DRD3 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.